The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $944,282 in first-year total cost, median $236,539.
Most frequent study sections
- Special Emphasis Panel[ZAR1 YL (M2)]4
Most frequent institutions
- BIOSTRATEGIES, LC1
- ETHOS RESEARCH AND DEVELOPMENT, LLC1
- NANOMEDIC, INC.1
- TENEOBIO, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery1R43AR077353-01 | CRAMER, CAROLE L.YANG, TIANHONG | BIOSTRATEGIES, LC, AR | $250,000 | ZAR1 |
| 2020 | Developing novel therapeutic approaches for osteopenia and osteoporosis in patients with sickle cell disease1R43AR077344-01 | LIU, GANG | NANOMEDIC, INC., UT | $248,486 | ZAR1 |
| 2020 | Development of a urinary biomarker panel and software-based solutions to optimize treatment strategies for Systemic Juvenile Idiopathic Arthritis.1R43AR077338-01 | GUNN, JOSHUA ADAM | ETHOS RESEARCH AND DEVELOPMENT, LLC, KY | $224,592 | ZAR1 |
| 2020 | Inhibition of CD38 NADase by anti-CD38 antibody: a novel therapy for systemic scleroderma1R43AR077336-01 | VAN SCHOOTEN, WILLEM | TENEOBIO, INC., CA | $221,204 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.